Oral nano vitamin D supplementation reduces disease activity in ulcerative colitis: A double-blind randomized parallel group placebo-controlled trial
Journal of Clinical Gastroenterology Aug 01, 2019
Ahamed ZR, Dutta U, Sharma V, et al. - Because vitamin D has anti-inflammatory characteristics and could be useful in ulcerative colitis (UC), researchers analyzed the impact of oral nano vitamin D3 supplementation on disease activity in active UC [ulcerative colitis disease activity index (UCDAI) ≥ 3]. For this investigation, they randomized patients with active UC and vitamin D <40 ng/mL to receive either oral nano vitamin D (60,000 IU/d×8 d) or placebo. Investigators found that the median vitamin D levels rose from 15.4 to 40.83 mg/dL in the vitamin D group and marginally from 13.45 to 18.85 mg/dL in controls. Increase in levels of vitamin D associated with a decrease in UCDAI score, C-reactive protein, and calprotectin. According to findings, oral nano vitamin D supplementation in active UC is connected with a decrease in disease activity and grade of severity and is seen more frequently in those who have attained a 40 ng/mL target vitamin D level.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries